- Home
- KOYN vs NGNE Comparison
KOYN vs NGNE Comparison
Compare KOYN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOYN | NGNE |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.9M | 327.8M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOYN | NGNE |
|---|---|---|
| Price | $10.01 | $18.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | 134.5K | ★ 152.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $6.88 |
| 52 Week High | $10.08 | $37.27 |
Technical Indicators
Market Signals| Indicator | KOYN | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 46.12 |
| Support Level | $10.00 | $18.12 |
| Resistance Level | $10.03 | $20.44 |
| Average True Range (ATR) | 0.02 | 1.23 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 55.56 | 50.38 |
Price Performance
Historical ComparisonAbout KOYN CSLM Digital Asset Acquisition Corp III Class A Ordinary Shares
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.